Postmarketing outsourcing worth over $1bn; Quintiles SVP

By Nick Taylor

- Last updated on GMT

Related tags Electronic health record Clinical trial

Quintiles and Cerner are combining their “unique sets of experience and expertise” to improve the efficiency of late phase research, the market for which exceeds $1bn (€677m), according to a SVP at the CRO.

Regulatory agencies in the US and Europe are putting more pressure on pharma to generate postmarketing data and, given the finite resources and economic pressures at companies, much of this work is being outsourced to contract research organisations (CRO).

Consequently the market for outsourced postmarketing studies now exceeds $1bn, according to Dipti Amin, senior vice president (SVP) of drug safety and medical affairs at Quintiles.

To improve its offering in this area Quintiles has teamed up with Cerner, a supplier of healthcare workflows and electronic health record (EHR) technology, to create “an integrated solution​”​for areas including patient registries, post-approval and late phase trials and observational studies.

Quintiles claims to conduct more clinical research than anyone else and this gives it the experience and expertise to conduct efficient, cost-effective postmarketing studies.

Drawing on this experience Quintiles designs postmarketing studies tailored to the geographic region and drug being investigated but Amin added that the overall safety focus remains the same, as does the need to identify high risk patients and minimise the risk of side effects.

Sentinel Initiative

The US Food and Drug Administration (FDA) is in the process of establishing the Sentinel Initiative to provide a national, integrated, electronic system for monitoring the safety of drugs.

Amin explained that she personally, and Quintiles as an organisation, support the programme and endorse anything that helps improve patient safety, adding that the Sentinel Initiative goes some way to bettering the situation.

The system will access information from disparate databases to enhance the agency’s ability to monitor adverse events. Amin added that she believes the system could lead to an increase in postmarketing requirements.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more